Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1972 2
1979 2
1980 4
1981 2
1982 1
1983 3
1984 1
1985 2
1986 2
1987 2
1997 2
2000 1
2001 1
2006 1
2007 1
2008 1
2010 1
2013 1
2016 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, Croitoru AE, Ilieva RN, Natošević S, Nita AL, Kalev DN, Harpaz Z, Farbstein M, Silverman MH, Bristol D, Itzhak I, Fishman P. Stemmer SM, et al. Among authors: farbstein m. Cancers (Basel). 2021 Jan 7;13(2):187. doi: 10.3390/cancers13020187. Cancers (Basel). 2021. PMID: 33430312 Free PMC article.
Pseudohypoxemia due to leukemia and thrombocytosis.
Chillar RK, Belman MJ, Farbstein M. Chillar RK, et al. Among authors: farbstein m. N Engl J Med. 1980 Mar 6;302(10):584. doi: 10.1056/NEJM198003063021017. N Engl J Med. 1980. PMID: 7351901 No abstract available.
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV, Cosgarea MR, Morariu HS, Michael Z, Cristodor P, Nica C, Silverman MH, Bristol DR, Harpaz Z, Farbstein M, Cohen S, Fishman P. David M, et al. Among authors: farbstein m. J Drugs Dermatol. 2016 Aug 1;15(8):931-8. J Drugs Dermatol. 2016. PMID: 27537992 Clinical Trial.
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. Stemmer SM, et al. Among authors: farbstein m. Oncologist. 2013;18(1):25-6. doi: 10.1634/theoncologist.2012-0211. Epub 2013 Jan 8. Oncologist. 2013. PMID: 23299770 Free PMC article. Clinical Trial.
Pre-illness dietary factors in inflammatory bowel disease.
Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Reif S, et al. Among authors: farbstein m. Gut. 1997 Jun;40(6):754-60. doi: 10.1136/gut.40.6.754. Gut. 1997. PMID: 9245929 Free PMC article.
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman MH, Kerns WD, Bristol DR, Cohn I, Fishman P. Avni I, et al. Among authors: farbstein m. Ophthalmology. 2010 Jul;117(7):1287-93. doi: 10.1016/j.ophtha.2009.11.029. Epub 2010 Mar 20. Ophthalmology. 2010. PMID: 20304499 Free PMC article. Clinical Trial.
Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.
Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman P. Ochaion A, et al. Among authors: farbstein m. Arthritis Res Ther. 2006;8(6):R169. doi: 10.1186/ar2078. Arthritis Res Ther. 2006. PMID: 17101059 Free PMC article.
Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia.
Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL. Blume KG, et al. Among authors: farbstein mj. N Engl J Med. 1980 May 8;302(19):1041-6. doi: 10.1056/NEJM198005083021901. N Engl J Med. 1980. PMID: 6245359
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P. Silverman MH, et al. Among authors: farbstein m. J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15. J Rheumatol. 2008. PMID: 18050382 Clinical Trial.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page